Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems

The major sporozoite surface antigen of Theileria annulata (SPAG-1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG-1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both beta-galactosidase and hepatitis B core antigen fusions or as a full-length form expressed as a GST fusion with an N terminal His6 tag. Different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham were used, which are called SKBA. The data point to the conclusion that SPAG-1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.

Bibliographic Details

Main Authors:	Boulter, N., Brown, D., Wilkie, G., Williamson, S., Kirvar, E., Knight, P., Glass, E., Campbell, J., Morzaria, S.P., Nene, Vishvanath, Musoke, A.J., Oliveria, C. de, Gubbels, M.J., Jongejan, F., Hall, R.
Format:	Journal Article biblioteca
Language:	English
Published:	Wiley 1999-09
Subjects:	theileria parva, vaccines, antigens, sporozoites, immunization, calves,
Online Access:	https://hdl.handle.net/10568/29793 https://doi.org/10.1046/j.1365-3156.1999.00453.x
Tags:	Add Tag No Tags, Be the first to tag this record!